Early research (Phase 1)Study completedNCT03821233What this trial is testingA Dose Finding Study of ZW49 in Patients With HER2-Positive CancersWho this might be right forHER2-expressing Cancers Zymeworks BC Inc. 112
Testing effectiveness (Phase 2)Ended earlyNCT05091528What this trial is testingA Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersWho this might be right forHER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more Silverback Therapeutics 2
Early research (Phase 1)Study completedNCT02576548What this trial is testingMEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.Who this might be right forHER2 Expressing Breast or Gastric/Stomach Cancers MedImmune LLC 47
Testing effectiveness (Phase 2)WithdrawnNCT04464967What this trial is testingSafety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWho this might be right forAdvanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more NKGen Biotech, Inc.
Early research (Phase 1)Looking for participantsNCT05969041What this trial is testingStudy of MT-302 in Adults With Advanced or Metastatic Epithelial TumorsWho this might be right forEpithelial Tumors, Malignant Myeloid Therapeutics 48
Early research (Phase 1)Active Not RecruitingNCT06714617What this trial is testingEvaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsWho this might be right forBreast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more SystImmune Inc. 120
Early research (Phase 1)Looking for participantsNCT04704661What this trial is testingTesting the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialWho this might be right forAdvanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more National Cancer Institute (NCI) 51
Early research (Phase 1)Study completedNCT02892123What this trial is testingTrial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersWho this might be right forHER2-expressing Cancers Jazz Pharmaceuticals 279
Early research (Phase 1)Study completedNCT00291473What this trial is testingSafety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing CancersWho this might be right forEsophageal CancerLung CancerStomach Cancer+2 more Ludwig Institute for Cancer Research 9
Testing effectiveness (Phase 2)Study completedNCT03602079What this trial is testingStudy of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneWho this might be right forHER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more Klus Pharma Inc. 49
Early research (Phase 1)Study completedNCT04319757What this trial is testingACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid TumorsWho this might be right forLocally Advanced Solid TumorMetastatic CancerSolid Tumor+2 more Acepodia Biotech, Inc. 12
Testing effectiveness (Phase 2)Looking for participantsNCT06271837What this trial is testingT-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsWho this might be right forAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) AstraZeneca 175